In groundbreaking research published in Nature Metabolism, Xu and his team reveal that activating TGR5 curtails cardiolipotoxicity and enhances cardiac function in diabetic mice, proposing it as a viable therapeutic target for diabetic cardiomyopathy (Wang et al. 2024). This evidence concerns the gene GPBAR1 and diabetic cardiomyopathy.